{{--
  Back to User
--}}
{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode'])) Logout @endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
Back

To understand and evaluate the PerceptiOn of evolving staNdards of care in Diabetes management (POND)

Survey Questionnaire Form
Doctor's details
@if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif

Questionnaire

  1. From your clinical practice, which class of medication do you most commonly prescribe as first-line therapy for Type 2 diabetes? *

  2. In your practice, what percentage of your patients with Type 2 diabetes are on insulin therapy? *

  3. What are the key factors you consider when choosing an initial medication for newly diagnosed Type 2 diabetes patients? *
  4. Which SGLT-2 inhibitor do you prefer for your patients, in your clinical practice? *

  5. How important, from your clinical perspective, is lifestyle modification in the management of Type 2 diabetes? *

  6. Do you recommend bariatric surgery for patients with Type 2 diabetes and obesity, based on your clinical practice? *

  7. How do you tailor diabetes treatment plans to meet the unique needs of individual patients? *
  8. In your opinion, which of the following is the most critical in diabetes management? *

  9. Which GLP-1 receptor agonist do you prescribe most frequently, based on your clinical experience? *

  10. What are the most common barriers to achieving glycemic control in your patients with Type 2 diabetes? *
  11. How often do you monitor for diabetes status by measuring blood sugar or HbA1c levels in your clinical practice? *

  12. What is your primary goal for HbA1c levels in most patients with Type 2 diabetes, based on your clinical practice? *

  13. How do you approach the management of diabetes in patients with a history of cardiovascular disease? *
  14. Do you utilize telemedicine for diabetes management, based on your clinical approach? *

  15. Which factor most influences your choice of diabetes medication, based on your clinical judgment? *

  16. What strategies do you use to improve medication adherence among your diabetes patients? *
  17. What is your preferred approach for managing diabetic neuropathy, based on your clinical practice? *

  18. Which of the following comorbid conditions do you prioritize managing alongside diabetes, based on your clinical practice? *

  19. How often do you discuss the potential side effects of diabetes medications with your patients, based on your clinical interactions? *

  20. What are your thoughts on the use of continuous glucose monitoring systems in diabetes care? Kindly share about the use of continuous glucose monitoring in your patients. *
  21. What percentage of your patients with diabetes receive regular eye examination, based on your clinical practice? *

  22. How do you integrate dietary recommendations into your diabetes management plans? *
  23. Which dietary approach do you most frequently recommend to your patients with diabetes, based on your clinical experience? *

  24. How often do you collaborate with dietitians, in managing diabetes, based on your clinical practice? *

  25. What is the biggest challenge you face in managing patients with diabetes, based on your clinical experience? *

  26. In your clinical practice, what percentage of patients are prescribed the combination of dapagliflozin and linagliptin for Type 2 diabetes management? *

  27. From your clinical experience, what is your primary reason for prescribing the dapagliflozin and linagliptin combination? *

  28. Based on your experience, how effective is the combination of dapagliflozin and linagliptin in lowering HbA1c? *

  29. What percentage of your patients, based on your clinical judgment, experience significant weight loss with the dapagliflozin and linagliptin combination? *

  30. In your clinical experience, which side effect do you encounter most frequently with the dapagliflozin and linagliptin combination? *

  31. How often do you, monitor renal function in patients on the dapagliflozin and linagliptin combination? *

  32. What are the primary benefits you see from using combination therapies in diabetes management? *
  33. How do you handle cases where patients have multiple comorbidities with diabetes treatment? Give us a case scenario of your patient who is successfully managed recently. *
  34. Do you consider the dapagliflozin and linagliptin combination cost-effective for your patients, based on your clinical judgment? *

  35. How do you rate the dapagliflozin and linagliptin combination's efficacy in reducing cardiovascular risk in diabetic patients, from your clinical perspective? *

  36. What is your approach to managing diabetes in elderly patients with multiple health issues? *
  37. Which patient population, in your clinical experience, do you find most suitable for the dapagliflozin and linagliptin combination as first line? *

  38. How do you balance the goals of glycemic control and minimizing side effects in your treatment plans? *
  39. Do you observe a reduced need for additional antihyperglycemic agents in patients on dapagliflozin and linagliptin combination, based on your clinical experience? *

  40. How do you manage the risk of genital-urinary infections in patients taking dapagliflozin, based on your clinical approach? *

  41. How do you manage diabetes care during periods of acute illness or hospitalization for your patients? *
  42. What is the average duration of treatment with the dapagliflozin and linagliptin combination in your practice, based on your clinical experience? *

  43. In your experience, which complication do you prioritize the most in the management of type 2 diabetes? *

  44. How frequently do you, based on your clinical practice, screen for diabetic retinopathy in your patients? *

  45. How do you evaluate and manage the long-term complications of diabetes in your patients? *
  46. What is your preferred method, based on your clinical experience, for screening for diabetic nephropathy? *

  47. How often do you, based on your clinical practice, refer patients to a dietitian for nutritional counseling? *

  48. What are the key factors you consider when prescribing newer diabetes medications like GLP-1 receptor agonists or SGLT-2 inhibitors? *
  49. Do you, based on your clinical practice, utilize technology (e.g., apps, continuous glucose monitors) to help prevent complications? *

  50. How do you assess and manage the risk of hypoglycemia in your patients on intensive insulin therapy? Give us in detail with a recent case managed by you. *